Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model

Marilyn F. Dille, Garnett P. McMillan, Kelly M. Reavis, Peter Jacobs, Stephen A. Fausti, Dawn Konrad-Martin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

An objective method for identifying ototoxic hearing loss among patients receiving cisplatin is necessary since the ability of patients to take a behavioral test may change over the course of treatment. Data from 56 monitoring visits by 19 Veterans taking cisplatin were used to identify combinations of distortion-product otoacoustic emission (DPOAE) metrics and ototoxicity risk factors that best identified ototoxic hearing loss. Models were tested that incorporated DPOAE metrics generated statistically using partial least-squares analysis. Models were also tested that incorporated a priori DPOAE change criteria, such as a minimum DPOAE level shift of 6 dB. Receiver Operating Characteristic analysis was used to compare the accuracy of these models. The best performing model incorporated weighted combinations of pre-treatment hearing, cumulative cisplatin dose and DPOAE metrics that were determined using partial least-squares and evaluated over a quarter octave range near each subjects' high frequency DPOAE limit. Using this model and the DPOAE recording methods described herein, the chance of ototoxic hearing change can be determined at any given observed change in DPOAE level. This approach appears to provide an accurate and rapid ototoxicity risk assessment (ORA) that once validated can be used clinically.

Original languageEnglish (US)
Pages (from-to)1163-1174
Number of pages12
JournalJournal of the Acoustical Society of America
Volume128
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

risk assessment
dosage
products
auditory defects
hearing
Risk Assessment
Dose
octaves
pretreatment
receivers
recording
shift

ASJC Scopus subject areas

  • Acoustics and Ultrasonics

Cite this

Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model. / Dille, Marilyn F.; McMillan, Garnett P.; Reavis, Kelly M.; Jacobs, Peter; Fausti, Stephen A.; Konrad-Martin, Dawn.

In: Journal of the Acoustical Society of America, Vol. 128, No. 3, 09.2010, p. 1163-1174.

Research output: Contribution to journalArticle

Dille, Marilyn F. ; McMillan, Garnett P. ; Reavis, Kelly M. ; Jacobs, Peter ; Fausti, Stephen A. ; Konrad-Martin, Dawn. / Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model. In: Journal of the Acoustical Society of America. 2010 ; Vol. 128, No. 3. pp. 1163-1174.
@article{6e29e55899d340fea6007f8330813f1e,
title = "Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model",
abstract = "An objective method for identifying ototoxic hearing loss among patients receiving cisplatin is necessary since the ability of patients to take a behavioral test may change over the course of treatment. Data from 56 monitoring visits by 19 Veterans taking cisplatin were used to identify combinations of distortion-product otoacoustic emission (DPOAE) metrics and ototoxicity risk factors that best identified ototoxic hearing loss. Models were tested that incorporated DPOAE metrics generated statistically using partial least-squares analysis. Models were also tested that incorporated a priori DPOAE change criteria, such as a minimum DPOAE level shift of 6 dB. Receiver Operating Characteristic analysis was used to compare the accuracy of these models. The best performing model incorporated weighted combinations of pre-treatment hearing, cumulative cisplatin dose and DPOAE metrics that were determined using partial least-squares and evaluated over a quarter octave range near each subjects' high frequency DPOAE limit. Using this model and the DPOAE recording methods described herein, the chance of ototoxic hearing change can be determined at any given observed change in DPOAE level. This approach appears to provide an accurate and rapid ototoxicity risk assessment (ORA) that once validated can be used clinically.",
author = "Dille, {Marilyn F.} and McMillan, {Garnett P.} and Reavis, {Kelly M.} and Peter Jacobs and Fausti, {Stephen A.} and Dawn Konrad-Martin",
year = "2010",
month = "9",
doi = "10.1121/1.3473693",
language = "English (US)",
volume = "128",
pages = "1163--1174",
journal = "Journal of the Acoustical Society of America",
issn = "0001-4966",
publisher = "Acoustical Society of America",
number = "3",

}

TY - JOUR

T1 - Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model

AU - Dille, Marilyn F.

AU - McMillan, Garnett P.

AU - Reavis, Kelly M.

AU - Jacobs, Peter

AU - Fausti, Stephen A.

AU - Konrad-Martin, Dawn

PY - 2010/9

Y1 - 2010/9

N2 - An objective method for identifying ototoxic hearing loss among patients receiving cisplatin is necessary since the ability of patients to take a behavioral test may change over the course of treatment. Data from 56 monitoring visits by 19 Veterans taking cisplatin were used to identify combinations of distortion-product otoacoustic emission (DPOAE) metrics and ototoxicity risk factors that best identified ototoxic hearing loss. Models were tested that incorporated DPOAE metrics generated statistically using partial least-squares analysis. Models were also tested that incorporated a priori DPOAE change criteria, such as a minimum DPOAE level shift of 6 dB. Receiver Operating Characteristic analysis was used to compare the accuracy of these models. The best performing model incorporated weighted combinations of pre-treatment hearing, cumulative cisplatin dose and DPOAE metrics that were determined using partial least-squares and evaluated over a quarter octave range near each subjects' high frequency DPOAE limit. Using this model and the DPOAE recording methods described herein, the chance of ototoxic hearing change can be determined at any given observed change in DPOAE level. This approach appears to provide an accurate and rapid ototoxicity risk assessment (ORA) that once validated can be used clinically.

AB - An objective method for identifying ototoxic hearing loss among patients receiving cisplatin is necessary since the ability of patients to take a behavioral test may change over the course of treatment. Data from 56 monitoring visits by 19 Veterans taking cisplatin were used to identify combinations of distortion-product otoacoustic emission (DPOAE) metrics and ototoxicity risk factors that best identified ototoxic hearing loss. Models were tested that incorporated DPOAE metrics generated statistically using partial least-squares analysis. Models were also tested that incorporated a priori DPOAE change criteria, such as a minimum DPOAE level shift of 6 dB. Receiver Operating Characteristic analysis was used to compare the accuracy of these models. The best performing model incorporated weighted combinations of pre-treatment hearing, cumulative cisplatin dose and DPOAE metrics that were determined using partial least-squares and evaluated over a quarter octave range near each subjects' high frequency DPOAE limit. Using this model and the DPOAE recording methods described herein, the chance of ototoxic hearing change can be determined at any given observed change in DPOAE level. This approach appears to provide an accurate and rapid ototoxicity risk assessment (ORA) that once validated can be used clinically.

UR - http://www.scopus.com/inward/record.url?scp=77956404890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956404890&partnerID=8YFLogxK

U2 - 10.1121/1.3473693

DO - 10.1121/1.3473693

M3 - Article

C2 - 20815453

AN - SCOPUS:77956404890

VL - 128

SP - 1163

EP - 1174

JO - Journal of the Acoustical Society of America

JF - Journal of the Acoustical Society of America

SN - 0001-4966

IS - 3

ER -